VoltarenRGel is owned and licensed by Novartis AGSANCTURAR and its XR version for treatment of overactive bladder VANTASRfor the palliative treatment

Voltaren(R)Gel is owned and licensed by Novartis AG;SANCTURA(R) and its XR version for treatment of overactive bladder, VANTAS(R)for the palliative treatment of advanced prostate cancer, and SUPPRELIN(R) LAfor the treatment of early onset puberty in children.The company markets itsbranded pharmaceutical products to physicians in pain management, neurology,surgery, oncology, and primary care. and acquired 100% of the outstanding shares of Indevusfor a purchase price of $4.50 per share in cash and the non-transferablecontractual right to receive up to an additional $3.00 per share in cashpayable in the future upon achievement of certain regulatory and salesmilestones.The results of operations for Indevus have been included in ourconsolidated operating results beginning on February 23, 2009.Conference Call InformationEndo will conduct a conference call with financial analysts to discuss thisnews release today at 10:30 a.m. During the firstquarter of 2009, the company benefited from a market shortfall in the supplyfor certain generic products.Acquisition of Indevus Pharmaceuticals, Inc.During the first quarter of 2009, we completed our acquisition of IndevusPharmaceuticals, Inc. Net Sales of VANTAS(R)applicable to Endo results for the first quarter were $1.9 million. Southern Company cautions that there are certainfactors that can cause actual results to differ materially from theforward-looking information that has been provided.

Southern Company brands are known for excellent customerservice, high reliability and retail electric prices that are below thenational average. producer of electricity,Southern Company owns electric utilities in four states and a growingcompetitive generation company, as well as fiber optics and wirelesscommunications. ATLANTA, April 29 /PRNewswire-FirstCall/ — Southern Company (NYSE: SO) todayreported first quarter earnings of $125.7 million, or 16 cents a share,compared with $359.2 million, or 47 cents a share, in the same period a yearago. Hensick forced Hasek to make a save 11:20 into the game.Detroit had a 14-3 shot advantage in first period. The Nostradamas’ of football never thought Lou Holtz would stay seven years on the Hill, who knows?Just so all those “experts” in Atlanta don’t think I’m alone in my assessment of the Falcons, here is a link they might find interesting.

Apparently not all, judging by the comments left on this article by jilted Atlanta Falcon fans.In my debut article on this site, the whole point was ESPN’s double standard concerning Petrino’s departure from Atlanta contrasted with Rich(er) Rodriguez’ messy exit from West Virginia This writer was called an “idoit” among other  things I assume he or she meant I-D-I-O-T There were a number of other asinine comments In other words, it was a successful debut. Although the Lakers have not had problems scoring (they average 106 points per game), Gasol just makes the team stronger. Los Angeles sent Kwame Brown, Javaris Crittenton, and two first round picks to the Memphis Grizzlies in exchange for the seven-footer. duty-free shops and U.S.overseas military bases from All Other.Conwood is the second largest smokeless tobacco products manufacturer inthe United States.Management uses “adjusted” (non-GAAP) measurements to set performancegoals and to measure the performance of the company, and believes thatinvestors’ understanding of the underlying performance of the company’scontinuing operations is enhanced through the disclosure of these metrics. Stockdale, who became Conwood’s presidentand chief executive officer on Feb.

More information, including this and pastpress releases of Endo Pharmaceuticals, is available at Harbor StatementThis press release contains forward-looking statements within the meaning ofthe Private Securities Litigation Reform Act of 1995 regarding, among otherthings,the acquisition of Indevus, the company’s financial position, resultsof operations, market position, product development and business strategy, aswell as estimates of future net sales, future expenses, future net income andfuture earnings per share.Statements including words such as “believes,”"expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,”"intend,” “guidance” or similar expressions are forward-looking statements. 2008 – 31 March 2008 Net profit/loss-31 58352 351Other comprehensive income:-8 771 2 511 Revaluation of fixed assets00 Increases due to revaluation 1 122379 of securities available for sale (net of tax) Net income of hedging-19 6002 132 derivatives (net of tax)Net income from released 9 7070 hedging instrument (after deferred tax) Total comprehensive income -40 35454 862Total incom attributable: 1 to minority interest2 2005 298 2. -33 783 47 053Attributabl e to equity holders of the CompanyNet-33 783 000 47 053 000profit/loss attributabl e to equity holders of the Company (PLN)Weighted 28 716 23028 716 230averagenumber ofordinary shares Earnings/lo -1,18 1,64sses per ordinary share (PLN)Diluted28 716 23028 716 230weighted averagenumber ofordinary shares Diluted-1,18 1,64earnings/lo sses per ordinary share (PLN)OTHER COMPREHENSIVE INCOME PLN`0001st quarter1st quarter1 Jan 2009 – 31 March 20091 Jan. 2008 – 31 March20092008 Interest 218 737 186 795 income Interest -127 593-71 489 expenses Net2 91 144115 306 interest income Impairment 3 -16 503 -7 716charge Net74 641107 590 interest income incl.impairment chargesFee and117 354 117 545 commission income Fee and-25 607 -31 691 commission expenses Net fee and 4 91 74785 854commission income Dividends0 0 Net trading 5 38 98632 383income and revaluation Net income 6 1 379 1 007 from investments General7 -248 711-192 444administrat iveexpenses Result on8 1 653 33 371operatingincome and expenses Gross-40 305 67 761profit/loss Income tax 8 722 -15 410 expenseNet-31 583 52 351profit/loss :1 2 200 5 298 Attributabl e to minority interest 2. * Selected consolidated profit and loss account amounts and consolidated cashflow statement – translated using the average rate of exchange, which is anarithmetic mean of the average rates announced by the Central Bank and at theend of each month of first quarters; 2009 – 4.5994, 2008 – 3.5574.INTERIM FINANCIAL STATEMENTS OF THE BANK BPH GROUPCONSOLIDATED STATEMENT OF COMPREHENSIVE INCOMECONSOLIDATED INCOME STATEMENTPLN’000Notes 1st quarter 1st quarter1 Jan 2009 – 31 March1 Jan. Diluted earnings/losses per ordinary share attributable to-1.18 1.64-0.260.46 equity holders of the Company (PLN/EUR) XXI. Dividend paid per ordinary share (PLN/EUR) 0.000.000.00 0.00Individual positions of the consolidated financial statement of Bank BPH SA wereconverted into EURO according to the following principles:* Selected consolidated balance positions and book value per share – translatedusing the average EURO exchange rate in PLN announced by the Central Bank on thebalance sheet day: 31.03.2009 – 4.7013; 31.03.2008 – 3.5258.